Contraception
Volume 82, Issue 2 , Pages 139-146 , August 2010

Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome

  • Alka Kriplani

      Affiliations

    • Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi 110029, India
    • Corresponding Author InformationCorresponding author. Tel.: +91 11 26594933, +91 26589883, +91 9810828717; fax: +91 11 26588641, +91 26588663.
    • ,
  • Anurekha Janaki Periyasamy

      Affiliations

    • Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi 110029, India
    • ,
  • Nutan Agarwal

      Affiliations

    • Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi 110029, India
    • ,
  • Vidushi Kulshrestha

      Affiliations

    • Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi 110029, India
    • ,
  • Anand Kumar

      Affiliations

    • Department of Reproductive Endocrinology, All India Institute of Medical Sciences, New Delhi 110029, India
    • ,
  • Ariachery Chinnama Ammini

      Affiliations

    • Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi 110029, India

Received 25 September 2009 ,Revised 28 January 2010 ,Accepted 4 February 2010.

References 

  1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–2749
  2. Vrbikova J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update. 2005;11:277–291
  3. Hillard PJ. Oral contraceptives and the management of hyperandrogenism-polycystic ovary syndrome in adolescents. Endocrinol Metab Clin North Am. 2005;34:707–723
  4. Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am. 2005;34:677–705
  5. Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:737–754
  6. Oelkers W. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone. Eur J Contracept Reprod Health Care. 2002;7:19–26
  7. Apter D, Borsos A, Baumgartner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care. 2003;8:37–51
  8. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25
  9. Michaelsson G, Juhlin L, Vahlquist A. Effects of oral zinc and vitamin A in acne. Arch Dermatol. 1977;113:31–36
  10. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–1447
  11. Morris PD, Mulkin CJ, Channer KS, Jones TH. A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men. Eur J Endocrinol. 2004;151:241–249
  12. Fotherby K, Caldwell AD. New progestogens in oral contraception. Contraception. 1994;49:1–32
  13. Darney PD. The androgenicity of progestins. Am J Med. 1995;98(suppl):104–110
  14. Cerel-Suhl SL, Yeager BF. Update on oral contraceptive pills. Am Fam Physician. 1999;60:2073–2084
  15. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of new oral contraceptive containing an antimineralocorticoid progestogen drospirenone on the rennin-aldosterone system, body weight, blood pressure, glucose tolerance and lipid metabolism. J Clin Endocrinol Metab. 1995;80:1816–1821
  16. Palep-Singh M, Mook K, Barth J, Balen A. An observational study of Yasmin in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care. 2004;30:163–165
  17. Guido M, Romualdi D, Giuliani M, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab. 2004;89:2817–2823
  18. Van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhoea. Cutis. 2002;69(4 Suppl):2–15
  19. Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long term treatment of hirsutism. Fertil Steril. 2006;85:436–440
  20. McFarlane KJ, Ise C, Linton C. Polycystic ovarian syndrome and insulin resistance. Clin Fam Pract. 2002;4(3):623–626
  21. Magnotti M, Futterweit W. Obesity and the polycystic ovary syndrome. Med Clin North Am. 2007;(91):1151–1168
  22. Perez-Lopez FR. Clinical experiences with drospirenone: from reproductive to postmenopausal years. Maturitas. 2008;60:78–91
  23. Ludicke F, Johannisson E, Helmerhorst FM, Campana A, Foidart J, Heithecker R. Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 microg of ethinyl estradiol on the human endometrium. Fertil Steril. 2001;76:102–107
  24. ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod. 2001;16:1527–1535
  25. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 2000;61:105–111
  26. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception. 2005;71:409–416
  27. Ibanez L, Zegher FD. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab. 2004;89:1592–1597
  28. Gaspard U, Scheen A, Endrikat J, et al. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception. 2003;67:423–429
  29. De Leo V, Morgante G, Piomboni P, Musacchio MC, Petraglia F, Cianci A. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. Fertil Steril. 2007;88:113–117
  30. Bachmann G, Sulak PJ, Sampson-Landers C, Benda N, Marr J. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception. 2004;70:191–198

PII: S0010-7824(10)00053-3

doi: 10.1016/j.contraception.2010.02.009

Contraception
Volume 82, Issue 2 , Pages 139-146 , August 2010

Article Tools

* Image Usage & Resolution